Clinical Trial Detail

NCT ID NCT02038010
Title BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx
Recruitment Completed
Gender female
Phase Phase I
Variant Requirements Yes
Sponsors Northwestern University
Indications

Her2-receptor positive breast cancer

Therapies

Ado-trastuzumab emtansine + Alpelisib

Age Groups: senior adult

Additional content available in CKB BOOST